Epidiolex is the first and only FDA-approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).
Objectives
Describe basic seizure management in LTC settings that care for individuals with I/DD
Define characteristics of LGS in children and adults
Review the medication Epidiolex in terms of efficacy as well as the guidelines for management of potential side effects
Identify the BECOME study outcomes from a non-clinical perspective of potential changes in behavior, cognition, physical attributes, and emotional changes that can be seen secondary to the initiation of Epidiolex to treat seizures
Presenter
Nanette Wrobel, Director of Business Development, Tarrytown Expocare Pharmacy
Stay Informed on the Latest Research & Analysis from ANCOR
